Tag: Parliamentary Question

  • Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Mulholland on 2016-07-21.

    To ask the Secretary of State for Health, what recent estimate he has made of the number of people in the UK affected by each strand of the hepatitis virus.

    Nicola Blackwood

    Public Health England receives laboratory reports of confirmed cases of hepatitis A, C and E from England and Wales and from England for hepatitis B.

    In 2014, 300 reports were received for hepatitis A, 488 for hepatitis B, 11,997 for hepatitis C and 886 for hepatitis E.

  • Richard Burden – 2016 Parliamentary Question to the Ministry of Defence

    Richard Burden – 2016 Parliamentary Question to the Ministry of Defence

    The below Parliamentary question was asked by Richard Burden on 2016-10-07.

    To ask the Secretary of State for Defence, how many military service complaints on the reversion of rank have been (a) made and (b) upheld in each of the last three years.

    Harriett Baldwin

    This information is not available in the format requested. The number of individuals who have raised service complaints regarding the reversion of rank is fewer than five in any year, which is deemed low enough to risk identification of the individuals in question.

  • Mark Menzies – 2015 Parliamentary Question to the Ministry of Justice

    Mark Menzies – 2015 Parliamentary Question to the Ministry of Justice

    The below Parliamentary question was asked by Mark Menzies on 2015-10-28.

    To ask the Secretary of State for Justice, what plans he has to improve the provision of work in prisons; and if he will make a statement.

    Andrew Selous

    We want prisons to be places of hard work, rigorous education and high ambition, with incentives for prisoners to learn and for prison staff to prioritise education and work. Improvements have been made to increase work but we want to go further. We are looking at the ways in which this might be achieved.

  • Bill Esterson – 2015 Parliamentary Question to the Ministry of Justice

    Bill Esterson – 2015 Parliamentary Question to the Ministry of Justice

    The below Parliamentary question was asked by Bill Esterson on 2015-11-24.

    To ask the Secretary of State for Justice, if he will make representations to the Criminal Cases Review Commission to open an investigation into the case of James Thompson.

    Mike Penning

    As I stated in response to Questions 14066 and 16560, although the Criminal Cases Review Commission is funded by my Department, it is entirely independent of Government, and Ministers cannot, and should not, attempt to intervene in its reviews or decisions.

  • John Healey – 2016 Parliamentary Question to the Department for Communities and Local Government

    John Healey – 2016 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by John Healey on 2016-01-05.

    To ask the Secretary of State for Communities and Local Government, what tendering and commissioning process was followed in selecting builders at the direct commissioning site at (a) Daedelus Waterfront, (b) Lower Grayling Well, (c) Connaught Barracks, (d) Northstowe and (e) Old Oak Common.

    Brandon Lewis

    These will be detailed commercial arrangements that will be established through a competitive procurement process. Existing public procurement processes will apply.

  • Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Mulholland on 2016-02-01.

    To ask the Secretary of State for Health, what arrangements there are for negotiating national prices for rare disease drugs that are not reviewed by NICE.

    George Freeman

    The prices of branded medicines to the health service, including those for rare disease drugs, are controlled by a voluntary and statutory scheme. The 2014 Pharmaceutical Price Regulation Scheme (PPRS) agreed a fixed level of growth on the vast majority of National Health Service spend on branded medicines with additional expenditure above this level paid for by the pharmaceutical companies. Over the first three years of the 2014 PPRS the UK Health services are expected to get back almost £1.8 billion in PPRS payments.

    It is NHS England’s responsibility to develop commissioning policies for treatments provided as part of prescribed specialised services, including some medicines for rare diseases. As part of the development of such policies, NHS England may take into account commercial offers manufacturers may make to the NHS. The Accelerated Access Review is looking with the National Institute for Health and Care Excellence at a range of new mechanisms for drug reimbursement adaptive pathways and managed access agreements.

  • Maggie Throup – 2016 Parliamentary Question to the Department of Health

    Maggie Throup – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Maggie Throup on 2016-02-23.

    To ask the Secretary of State for Health, what budget he plans to allocate to each clinical commissioning group in England to support the effective transfer of obesity surgery in April in a manner consistent with NICE’s clinical guidelines.

    George Freeman

    NHS England is not currently able to provide a figure for individual clinical commissioning groups on 1 April 2016 as the basis for calculating the figures is still being finalised.

  • Charlotte Leslie – 2016 Parliamentary Question to the Department of Health

    Charlotte Leslie – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Charlotte Leslie on 2016-03-18.

    To ask the Secretary of State for Health, what estimate he has made of the proportion of government NHS funding which primary care was allocated to in each of the last three years.

    Alistair Burt

    The table below shows the total National Health Service expenditure and total primary healthcare expenditure for the last three years for which audited outturn data is available. This includes primary medical care, primary dental services, primary eyecare services, community pharmacy and drugs prescribed in the community.

    The Department accounts data has been used as a consistent data source across primary care services. However, this excludes some funding streams to general medical practice, such as for out of hours services.

    Year

    NHS Revenue Expenditure under Clear Line of Sight Rules (£ billion)

    Expenditure on Primary Healthcare (£ billion)

    Primary Healthcare Expenditure as a % of NHS Revenue Expenditure

    2012-13

    102.57

    21.32

    20.79

    2013-14

    106.50

    21.32

    20.02

    2014-15

    110.56

    21.68

    19.61

  • Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Department for International Development

    Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Department for International Development

    The below Parliamentary question was asked by Baroness Kinnock of Holyhead on 2016-04-18.

    To ask Her Majesty’s Government what discussions have taken place with the government of Bangladesh about toxic, insanitary and unsafe working conditions in Hazaribagh, Dhaka.

    Baroness Verma

    The UK Government’s work around conditions in the leather industry in Bangladesh focuses on the issue of child labour. We support efforts in this particular area through the Manusher Johnno Foundation (MJF). MJF have campaigned successfully to include “Leather Works” on the Government of Bangladesh’s list of hazardous works for children. As a consequence, employers in the leather industry are now bound by a Code of Conduct which is aligned with the domestic Labour Law and National Child Labour Elimination Policy.

  • Seema Malhotra – 2016 Parliamentary Question to the HM Treasury

    Seema Malhotra – 2016 Parliamentary Question to the HM Treasury

    The below Parliamentary question was asked by Seema Malhotra on 2016-05-25.

    To ask Mr Chancellor of the Exchequer, what the average length of time between an application being made for a Venture Capital Trust Scheme and the scheme taking effect was in each of the last six years.

    Mr David Gauke

    The average time between a company applying to HM Revenue and Customs (HMRC) for approval as a Venture Capital Trust (VCT) and receiving approval in the last six tax years was as follows:

    Tax year

    Number of VCTs approved

    Average time taken to approve applications (days)

    2010-11

    16

    7

    2011-12

    6

    9

    2012-13 to 2015-16

    6

    16

    Notes

    1. The information for the years 2012-13 to 2015-16 has been grouped owing to the low numbers of VCTs seeking approval in each of those years. Disclosure of average times in each of those years could identify specific companies.

    2. The number of VCTs approved each year is provided in order to give context for the averages reported.

    3. The average time includes non-working days such as weekends and public holidays. Fractions of days are rounded up to the nearest day.

    4. The amount of time taken to approve a company as a VCT depends upon the specific facts of each case. Two cases in the period from 2012-13 to 2015-16 had significantly longer approval times, raising the average for this period. If those cases were excluded, the average time would have been 10 days.

    5. A company cannot raise funds from VCT investors until it has been listed on a regulated stock market. HMRC does not hold information about the date of listing although that information is publicly available.